Twist Bioscience三季度收入创新高并上调全年收入指引但本条为已处理财报催化重复转述

Earnings Call Insights: Twist Bioscience (TWST) Q3 fiscal 2026
Dr. Emily Leproust highlighted what she called the company’s “14th quarter of consistent growth with record revenue of $118.4 million, growth of 23% year-over-year,” and tied the quarter’s narrative to AI-enabled drug discovery, saying, “Today, we are seeing that opportunity mature into a durable growth engine.” (CEO Dr. Emily Leproust)
On AI-enabled discovery, Leproust reiterated the company’s Investor Day target and raised confidence as the year progresses, stating, “we guided to triple-digit percentage order growth for AI-enabled discovery in fiscal 2026 versus fiscal 2025,” and “we're increasingly confident that we will meet or exceed that target.” She also added a fiscal 2027 setup: “we believe that we have the potential to again post triple-digit percentage order growth for AI-enabled drug discovery in fiscal 2027 when compared to fiscal 2026.” (CEO Leproust)
Dr. Patrick Finn emphasized operating execution and manufacturing advantages as a core investment narrative, stating Twist’s platform “provides a structural advantage in cost, scale and speed,” and said that over the last 3 years the company “reduced manufacturing costs by 60%,” “reduced turnaround time by roughly 73%” and “increased oligonucleotide capacity fourfold.” (President & COO Dr. Patrick Finn)
Adam Laponis framed Q3 as progress toward profitability while sustaining growth: “Q3 was another quarter of consistent execution against the financial model we've laid out,” adding, “we focused on growing the top line while maintaining our commitment to adjusted EBITDA breakeven for the fourth quarter of fiscal 2026.” (CFO Adam Laponis)
Management raised full-year fiscal 2026 revenue guidance to “$456 million to $457 million,” and said Q4 revenue is expected to be “$123 million to $124 million,” with “sequential growth from both DSPS and NGS.” (CFO Laponis)
For Q4 segment direction, Laponis said, “We expect DSPS sequential growth to be driven by therapeutics and NGS to return to growth above 20% year-over-year,” while reiterating profitability timing: “we remain confident in our trajectory and continue to expect to achieve adjusted EBITDA breakeven this quarter.” (CFO Laponis)
Versus the prior quarter’s call, Twist shifted from forecasting Q3 revenue of “$114 million to $115 million” and fiscal 2026 revenue of “$442 million to $447 million” to a higher full-year range, while keeping the core milestone unchanged: “adjusted EBITDA breakeven for the fourth quarter of fiscal 2026.” (CFO Laponis; prior-quarter guidance cited from Q2 transcript)
The company reported Q3 gross margin of “52.8%,” and said the quarter benefited from scale, with Laponis noting “70% of incremental revenue dropping to the gross margin line.” (CFO Laponis)
By segment, DNA synthesis and Protein Solutions revenue was “$56.6 million” and NGS applications revenue was “approximately $61.8 million.” (CFO Laponis)
By industry, Laponis reported therapeutics revenue of “$40.4 million,” diagnostics revenue of “$43.8 million,” academic and government revenue of “$15.5 million,” and global supply partner revenue of “$12.9 million.” (CFO Laponis)
On profitability and liquidity, Twist reported “adjusted EBITDA was a loss of approximately $11.3 million,” and ended Q3 with “$166.8 million in cash, cash equivalents and short-term investments.” (CFO Laponis)
Brendan Smith, TD Cowen: Asked about therapeutics revenue ordering dynamics and what underpins fiscal 2027 “triple-digit” AI order growth; CEO Leproust said visibility is supported by customers “turning the crank,” new customers “coming on top of that,” and quote activity where “the number of sequences that they have in mind… give us very, very strong confidence.” (CEO Leproust)
Puneet Souda, Leerink: Asked about gene shipment growth vs. DSPS growth and AI order-to-revenue conversion plus the adjusted EBITDA bridge; CEO Leproust cited mix shift as “the growth comes primarily from antibody type sequences… those sequences are shorter,” while CFO Laponis said AI project timelines are “usually measured in weeks” and that in fiscal 2026 and into 2027 “the 2 metrics converge pretty nicely,” adding OpEx should improve after Q3 “one-timers.” (CEO Leproust; CFO Laponis)
David Westenberg, Piper Sandler: Pressed on sustaining adjusted EBITDA positivity in fiscal 2027 and asked about NGS product mix; CFO Laponis said full-year guidance will come in November and “we're not in the business typically of going backwards,” while COO Finn highlighted enzymes “featuring in our kits” and called out MRD tumor-informed demand where “people want more probes.” (CFO Laponis; COO Finn)
Subhalaxmi Nambi, Guggenheim: Asked for preliminary fiscal 2027 growth thoughts and clarified AI-order math; CFO Laponis responded, “Yes, you got that right,” and described “big chunky orders” and “hunger for data points,” while reiterating, “we're not guiding to 2027.” (CFO Laponis)
Kyle Mikson, Canaccord: Asked if competitor discounting is affecting therapeutics/AI and what drives the raised outlook; CEO Leproust said, “Frankly, no worries about competition at all,” and tied confidence to ability to deliver “thousands… in an array format” and “millions… in a pool format,” adding, “we would not guide to a triple-digit percent growth… for 2027 again… without very strong comparable customers.” (CEO Leproust)
Vijay Kumar, Evercore ISI: Asked why AI provides longer-term visibility than historical short-cycle ordering; CEO Leproust said AI involves “very, very big numbers,” leading to MSAs and deeper engagement, and concluded, “that's why we have more visibility than we had before.” (CEO Leproust)
Luke Sergott, Barclays: Asked about AI revenue disclosure and competitive context around TurboCHO; CEO Leproust argued differentiation is “around the breadth of the menu… the flexibility… and… what speed we can deliver that data,” while CFO Laponis said Twist has not provided “specific breakouts for AI-drug discovery quarter-on-quarter,” pointing instead to “outsized growth in therapeutics.” (CEO Leproust; CFO Laponis)
Robert Bamberger, Baird: Asked about the jump in academic and government results and promotions; COO Finn said it “remains a dynamic environment,” and added, “Express Genes and promotions into the segment continue.” (COO Finn)
Analyst sentiment was slightly skeptical, with repeated probing on AI durability, conversion, competition, and the sustainability of adjusted EBITDA improvement, including direct challenges such as “Is that having any impact… at all?” and requests to “double-click” on the EBITDA bridge. (Kyle Mikson, Canaccord; Puneet Souda, Leerink)
Management sentiment was positive and confident, leaning on scale, platform differentiation, and reaffirmed milestones, including statements like “we remain confident in our trajectory” and “Frankly, no worries about competition at all.” (CFO Laponis; CEO Leproust)
Compared with the prior quarter, management’s framing moved from “powered by continued strength in AI-enabled drug discovery” and staying “on track” for breakeven to stronger forward language around AI order growth “in fiscal 2027” and higher full-year revenue guidance, while maintaining the same breakeven timing. (CEO Leproust; CFO Laponis)
Guidance increased materially quarter-over-quarter, moving from fiscal 2026 revenue of “$442 million to $447 million” in Q2 to “$456 million to $457 million” in Q3, while the adjusted EBITDA milestone remained “breakeven… for the fourth quarter of fiscal 2026.” (CFO Laponis)
Strategically, Q2 emphasized external validation and partnerships such as “Amazon Web Services announced Twist as a wet lab partner,” and licensing “the B-Body bispecific platform,” while Q3 emphasized scaling AI-enabled discovery as a “durable growth engine,” expansion into new modalities, and broader claims on competitive moat and operational metrics. (CEO Leproust)
Analyst focus shifted from Q2’s concentration on AI order conversion and gross margin cadence to Q3’s heavier attention on therapeutic revenue sequencing, competitive discounting, and whether adjusted EBITDA can remain positive beyond Q4. (Q2 and Q3 Q&A)
Management cautioned that “the environment remains dynamic and order patterns may fluctuate,” particularly when discussing academic and government demand, even as it called the Q3 result evidence of “resilience.” (CFO Laponis)
Profitability execution risk remained a core topic, with management citing “approximately $2 million in employee transition costs” and “other onetime expenses” as drivers in Q3, while positioning Q4 OpEx improvement and continued revenue momentum as the bridge to “adjusted EBITDA breakeven.” (CFO Laponis)
Twist management framed Q3 around record $118.4 million revenue, accelerating AI-enabled discovery demand, and an updated fiscal 2026 outlook of $456 million to $457 million in revenue, while reiterating adjusted EBITDA breakeven in Q4. Management emphasized deeper AI customer engagement, large-scale sequence and data needs, and platform-driven operating improvements as the basis for confidence in continued growth and its stated goal of sustaining the breakeven commitment into fiscal 2027.